ADLINE
ADLINE CHEM LAB financials
- Market cap
- ₹8 Cr
Quarterly results
Q1 FY27: net profit up 180.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -0 | -0 | -0 | -0 | -0 +29% | -0 +70% | -0 −33% | -0 −33% |
| Net profit | -0 | -0 | 0 | -0 | -0 +22% | -0 +50% | -0 −143% | 0 +180% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −35.8% 1Y
1Y: ₹17.95 on 21 Aug 2025 → ₹11.52. High ₹17.95 (21 Aug 2025), low ₹7.6 (3 Dec 2025).
Financials, as filed
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Operating profit | ₹-0 Cr | ₹-0 Cr | ₹-0 Cr |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit | ₹-0 Cr | ₹-0 Cr | ₹-0 Cr |
| Cash from operations | ₹-0 Cr | ₹-0 Cr | ₹-0 Cr |
| Free cash flow | ₹-0 Cr | ₹-0 Cr | ₹-0 Cr |
| ROCE | — | — | -1266.7% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr |
| Reserves | ₹-4 Cr | ₹-3 Cr | ₹-7 Cr | ₹-7 Cr | ₹-7 Cr | ₹-8 Cr |
| Borrowings | ₹3 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr |
| Other liabilities | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Total liabilities | ₹6 Cr | ₹5 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Fixed assets | ₹4 Cr | ₹4 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Total assets | ₹6 Cr | ₹5 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters trimmed −3.76 pp while the public added +3.75 pp.
- Promoters
- 25.9%
- Public
- 74.1%
Since Jun 2025
- Promoters −3.76 pp
- Public +3.75 pp
How it drifted, 12 quarters
Over this window promoters fell from 28.2% to 25.9% — −2.4 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 28.2%, Public 71.8%.Dec '23: Promoters 28.2%, Public 71.8%.Mar '24: Promoters 29.6%, Public 70.4%.Jun '24: Promoters 29.6%, Public 70.4%.Sep '24: Promoters 29.6%, Public 70.4%.Dec '24: Promoters 29.6%, Public 70.4%.Mar '25: Promoters 29.6%, Public 70.4%.Jun '25: Promoters 29.6%, Public 70.4%.Sep '25: Promoters 29.6%, Public 70.4%.Dec '25: Promoters 25.9%, Public 74.2%.Mar '26: Promoters 25.9%, Public 74.2%.Jun '26: Promoters 25.9%, Public 74.1%.
Who is on the register
Named in the Jun 2026 filing
Every holder of ADLINE CHEM LAB LIMITED above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Hemant Amrish Parikh | 25.85% | unchanged |
| Sonal R Bambhania | 1.14% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse ADLINE CHEM LAB LIMITED
Guides on how to read this kind of business and the numbers that matter.